• Long non coding RNA as novel biomarkers for early diagnosis of Alzheimer’s disease
  • Atefe Yadollahi khales,1,* Kamran Ghaedi,2 FaribaEsmaeili,3 maryam noorbakhshnia,4
    1. Department of Biology, Faculty of Sciences, University of Isfahan, Hezar Jerib Ave., Azadi Square, Isfahan 81746-73441, Iran
    2. Department of Biology, Faculty of Sciences, University of Isfahan, Hezar Jerib Ave., Azadi Square, Isfahan 81746-73441, Iran
    3. Department of Biology, Faculty of Sciences, University of Isfahan, Hezar Jerib Ave., Azadi Square, Isfahan 81746-73441, Iran
    4. Department of Biology, Faculty of Sciences, University of Isfahan, Hezar Jerib Ave., Azadi Square, Isfahan 81746-73441, Iran


  • Introduction: Long non-coding RNA (LncRNA) have been reported to be involved in the pathogenesis of neurodegenerative diseases, but whether it can serve as a biomarker for Alzheimer disease (AD) is not yet known. Alzheimer’s disease (AD) is neurodegenerative disease with the highest incidence and the most common dementia among the elderly. we investigated the role of lncRNAs in Alzheimer’s disease and focus on some specific lncRNAs that may underlie Alzheimer’s disease pathophysiology and therefore could be potential diagnostic targets
  • Methods: The present study aimed to selected specific LncRNA as possible biomarkers for early diagnosis of Alzheimer’s disease by using both meta-analysis and bioinformatics methods. . Transcriptomic data were assessed from GEO and Array Express after systematic searches. The differentially expressed LncRNA from both DNA microarray and RNA sequencing datasets were analyzed and corroborated by met analysis. Statistically significant differentially expressed LncRNA were used for enrichment analysis based on KEGG and protein–protein interaction network analysis based on STRING.
  • Results: We found that the plasma LncRNA was significantly differentially expressed in of AD patients
  • Conclusion: LncRNAs have been discovered predominantly by high-throughput sequencing technologies,including microarrays and next-generation sequencing (NGS). lncRNAs are differentially expressed in AD patients, therefore can serve as biomarkers even potential treatment target for AD patients.
  • Keywords: Long non-coding RNA, Biomarker, Diagnosis, Alzheimer disease